We advised the management team of Theramex, the leading global specialty pharmaceuticals company focused on women’s health, on its sale by CVC Capital Partners VI (CVC) to global investment firms Carlyle and PAI Partners.
Theramex was created following the carve-out of a portfolio of women’s health pharma products in 2018 and has subsequently developed into one of the largest specialty pharma platforms dedicated to women and their health. The company provides patient-focused solutions across contraception, fertility, menopause, and osteoporosis with the aim of providing patients with products that can support them through their life journey.
With the support of Carlyle and PAI Partners, Theramex will seek to expand its diverse suite of products across existing and adjacent therapeutic areas and accelerate international expansion. The investment in Theramex builds on Carlyle’s long-term global focus on healthcare, a sector in which the firm has invested $15 billion to date.
Commenting on the transaction, Head of Private Equity Emma Danks said: "We are very proud to have supported the Theramex management team on this landmark transaction. Theramex is a true champion of women's health with a long history of delivering effective solutions and ensuring the availability of vital products. We look forward to seeing the business have an even greater impact on supporting women's health needs as it enters this next chapter of growth."
Robert Stewart, CEO of Theramex, added: “I am delighted to have the support of both Carlyle and PAI Partners investing in the business, which will allow us to further accelerate our growth. We would like to thank the team at Taylor Wessing for the exceptional support they gave us throughout this entire transaction. The innovative advice they provided was first class and demonstrated their significant expertise in private equity as well as the life sciences sector."
The transaction was led by partner Emma Danks with support from senior associate Suzy Davis and associate Kayla Sinclair in the private equity group.
Additional support was provided by partner Graham Samuel-Gibbon, senior counsel Clare Smith and Pip Moss in the tax & incentives team, and partner Colin McCall and senior associate Sumer Dayal in the IP team.
